By Fineline Cube 
Johnson & Johnson (J&J, NYSE: JNJ) announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) to update the label for TREMFYA® (guselkumab), an IL-23 antibody, to include evidence of inhibition of structural joint damage progression in adults with active psoriatic arthritis (PsA).
Regulatory Approval Details
| Item | Detail |
|---|---|
| Agency | FDA (United States) |
| Approval Type | Supplemental Biologics License Application (sBLA) |
| Product | TREMFYA® (guselkumab) – IL-23 antibody |
| Indication | Inhibition of structural joint damage progression in active psoriatic arthritis |
| Approval Date | 28 May 2026 |
| Supporting Data | 24-week results from Phase 3b APEX study |
Clinical Evidence – Phase 3b APEX Study
| Endpoint | Result (TREMFYA) | Comparator (Placebo) | Significance |
|---|---|---|---|
| Primary Endpoint | Met ACR20 response | Lower response rate | Statistically significant improvement in joint symptoms |
| Major Secondary Endpoint | Reduced structural damage progression (vdH-S score) | Greater progression | Demonstrated inhibition of radiographic joint damage |
| Crossover Analysis | 57% reduction in radiographic progression (Week 24-48) | Initial placebo group | Benefit observed even after disease progression |
| Safety Profile | Consistent with established profile | – | No new safety signals identified |
The APEX study specifically evaluated bio-naïve patients with active psoriatic arthritis, providing robust evidence for TREMFYA’s dual benefit on both symptomatic relief and structural preservation.
Market Impact & Strategic Implications
- PsA Treatment Landscape: TREMFYA becomes one of few biologics with explicit FDA-approved labeling for structural joint damage inhibition, creating a competitive differentiation in the $5.8 billion U.S. PsA market
- Commercial Advantage: The label expansion strengthens J&J’s position against competitors like AbbVie’s SKYRIZI and Amgen’s Otezla, which lack similar structural damage claims
- Physician Adoption: Rheumatologists now have regulatory-backed evidence to support early intervention with TREMFYA to prevent long-term joint destruction
- Revenue Potential: J&J projects incremental annual revenue of $300-400 million from expanded PsA indication, building on TREMFYA’s existing $2.1 billion global sales (2025)
Competitive Context
| Competitor | Product | Structural Damage Claim | Primary Mechanism |
|---|---|---|---|
| Johnson & Johnson | TREMFYA (guselkumab) | Yes (FDA-approved) | IL-23 inhibitor |
| AbbVie | SKYRIZI (risankizumab) | Limited data | IL-23 inhibitor |
| Amgen | Otezla (apremilast) | No | PDE4 inhibitor |
| Bristol Myers Squibb | Orencia (abatacept) | Yes | T-cell co-stimulation modulator |
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, clinical outcomes, and commercial expectations for TREMFYA. Actual results may differ due to risks including market competition, payer reimbursement decisions, and evolving treatment guidelines.-Fineline Info & Tech